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Parthenolide prevents resistance of MDA-MB231 cells to
doxorubicin and mitoxantrone: the role of Nrf2
Daniela Carlisi1,2, Anna De Blasio2,3, Rosa Drago-Ferrante2,3, Riccardo Di Fiore2,3,4, Giuseppina Buttitta2,3, Marco Morreale2,3,
Christian Scerri5,6, Renza Vento2,3,4 and Giovanni Tesoriere2,4
Triple-negative breast cancer is a group of aggressive cancers with poor prognosis owing to chemoresistance, recurrence and
metastasis. New strategies are required that could reduce chemoresistance and increases the effectiveness of chemotherapy. The
results presented in this paper, showing that parthenolide (PN) prevents drug resistance in MDA-MB231 cells, represent a
contribution to one of these possible strategies. MDA-MB231 cells, the most studied line of TNBC cells, were submitted to selection
treatment with mitoxantrone (Mitox) and doxorubicin (DOX). The presence of resistant cells was conﬁrmed through the
measurement of the resistance index. Cells submitted to this treatment exhibited a remarkable increment of NF-E2-related factor 2
(Nrf2) level, which was accompanied by upregulation of catalase, MnSOD, HSP70, Bcl-2 and P-glycoprotein. Moreover, as a
consequence of overexpression of Nrf2 and correlated proteins, drug-treated cells exhibited a much lower ability than parental cells
to generate ROS in response to a suitable stimulation. The addition of PN (2.0 μM) to Mitox and DOX, over the total selection time,
prevented both the induction of resistance and the overexpression of Nrf2 and correlated proteins, whereas the cells showed a
good ability to generate ROS in response to adequate stimulation. To demonstrate that Nrf2 exerted a crucial role in the induction
of resistance, the cells were transiently transfected with a speciﬁc small interfering RNA for Nrf2. Similarly to the effects induced by
PN, downregulation of Nrf2 was accompanied by reductions in the levels of catalase, MnSOD, HSP70 and Bcl-2, prevention of
chemoresistance and increased ability to generate ROS under stimulation. In conclusion, our results show that PN inhibited the
development of the resistance toward Mitox and DOX, and suggest that these effects were correlated with the prevention of the
overexpression of Nrf2 and its target proteins, which occurred in the cells submitted to drug treatment.
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INTRODUCTION
Breast cancer is the most frequent type of invasive malignancy in
female worldwide.1,2 Triple-negative breast cancer (TNBC) is a very
heterogeneous group of cancers, which includes forms lacking in
the expression of estrogen receptor, progesterone receptor and
human epidermal growth factor receptor 2 (HER 2). TNBCs, which
account for 12–17% of all breast cancers,3 prevalently affect young
women and are three times more frequent in African Americans
than in Caucasian women.4 As TNBCs are not sensitive to
endocrine therapy and HER 2 targeted therapy, standard
treatment is represented by surgery with radiotherapy and
adjuvant chemotherapy. TNBCs are very sensitive to chemother-
apy during the ﬁrst phase of treatment,5 successively the onset of
chemoresistance leads TNBC cells to elude the cytotoxic effects of
the drugs, developing a new relapsed form of the disease, often
complicated by the production of metastasis.6 Novel therapy
strategies are investigated5 to improve prognosis for TNBCs.
Doxorubicin (DOX) and Mitoxantrone (Mitox) are two antineo-
plastic drugs employed in the therapy of breast cancer. Both the
drugs are multiring planar molecules that intercalate with DNA
and inhibit the activity of topoisomerase II. DOX,7,8 which is
considered the most active agent in breast cancer therapy, is an
anthracycline antibiotic, whereas Mitox9,10 is a synthetic agent,
belonging to the class of anthracenediones. Treatment with DOX
or Mitox induces in most patients, after a positive response, the
development of chemoresistance, associated with recurrence of
the tumour form. The effectiveness of DOX is invalidated by
cardiotoxicity,11,12 which represents a serious problem when,
owing to the appearance of resistance against DOX, the patient is
treated with repeated and increasing doses of this drug.
Being a multifactorial phenomenon, chemoresistance has a
range of causes, which includes the following:13–15 activity of ATP-
binding cassette (ABC) transporters, such as P-glycoprotein16
(MDR1 and ABCB1) and ABCG2, which function as drug efﬂux
pumps and contrast the intracellular drug accumulation; activity of
the pro-survival members of Bcl-2 family;17 alteration of drug
target,18 as a consequence of mutation of some involved gene;
epigenetic modiﬁcations of genes;19 and ﬁnally acquisition of
resistance to apoptosis,20 due to downregulation of one or more
factors. Moreover, many factors and signalling pathways are
involved in chemoresistance. In particular, aldehyde
dehydrogenase,21 myc,22 Akt/PKB23 and Wnt/β-catenin24 path-
ways exert important roles in speciﬁc cases. With regard to TNBC
cells, chemoresistance has been attributed to senescent-like cells
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induced by therapeutic treatment.5 This event has been
interpreted as a strategy of cells to avoid the apoptotic process.
The transcription factor NF-E2-related factor 2 (Nrf2), which
regulates the expression of a battery of genes and is involved in
antioxidant and cytoprotective responses and in ATP-dependent
drug efﬂux pumps, is thought to have a crucial role in the control
of redox homeostasis and the cell protection against chemical and
radiation stress.25–27 Therefore, Nrf2 overexpression in tumour
cells favours development of chemoresistance. Consequently,
chemical inhibitors of Nrf2 can represent a new tool to prevent the
resistance induced in tumour cells by chemotherapeutic agents.
Parthenolide (PN), a sesquiterpene lactone found in Tanacetum
parthenium, known for its anti-inﬂammatory activity, exerts anti-
tumour effects on many cancer cells, whereas it is ineffective in
normal cells.28,29 Previously, we have shown that PN induced
cytotoxicity in MDA-MB231 cells,30 which are the most studied
TNBC cells, through the stimulation of oxidative stress and
autophagy. Moreover DMAPT, a soluble analogue of PN, markedly
decreased tumour growth in mice bearing xenografts of MDA-
MB231 cells and enhanced survival of treated mice.30 More
recently,31 we produced mammospheres from three distinct lines
of TNBCs and showed that both PN and DMAPT suppressed
production of spheres and induced cytotoxicity in stem-like cells
derived from their dissociation.
In this study we submitted MDA-MB231 cells to selection
treatment with DOX and Mitox, in order to produce resistant cells.
PN prevented the development of chemoresistance and the
overexpression of Nrf2 and correlated proteins found in selected
cells.
RESULTS
PN increased the cytotoxic effect of Mitox and DOX in MDA-
MB231 cells
Figure 1a shows the time course of the growth of cultured MDA-
MB231 cells compared with normal human mammary epithelial
cells (HMECs). Cell growth of the two lines increased progressively
with time, with MDA-MB231 cells growing much more rapidly
than HMEC. MDA-MB231 cells reached the conﬂuence (4.2 × 106
cells) at 10th day of culture, when the number of HMEC were only
5.8 × 105 cells. When 2.0 μM PN was added to the cultures a slower
progression of the growth was observed in comparison with
untreated cells (Figure 1a) with the difference being higher for
MDA-BM231 cells than for HMEC.
Mitox and DOX exert a strong cytotoxic effect on breast cancer
cells. The time courses of their effects on the viability of HMEC and
MDA-MB231 cells are shown in Figure 1b (Mitox) and 1c (DOX).
During the ﬁrst phase of treatment with either Mitox (0–4 days) or
DOX (0–10 days) MDA-MB231 cell number increased, although to
a degree that was much lower than for untreated cells (Figure 1a).
In the second phase, viability progressively decreased to very low
values with the decrease on Mitox treatment being greater and
more rapid than with DOX. Similarly, two phases were also
observed for HMEC, but the decrease during the second phase
was less rapid and less evident than with MDA-MB231 cells. For
instance, treatment with Mitox reduced MDA-MB231 cells to only
1.0 × 105 at the 20th day, whereas HMEC were reduced to
4.4 × 105. PN (2.0 μM) increased toxicity of both Mitox and DOX, so
that at the 20th day of treatment with Mitox and 40–42th day with
DOX viable cells were not identiﬁed any more in the cultures,
whereas when the cells were treated with the drugs alone without
PN a small amount of cells remained viable in the last phase of
treatment. We hypothesized that this difference was determined
by development of drug resistance and that PN prevented
this event.
Interestingly, during Mitox treatment monstrous, senescent-like
cells appeared by the 9th day of treatment and by the 20th day
reached about 30% of the total cells, whereas in cells treated with
DOX senescent-like cells appeared only by the 20th day. The
addition of PN did not substantially modify production of these
atypical cells.
Finally, the observation that the addition of PN to the drugs did
not cause signiﬁcant effects on HMEC (Figures 1b and c)
conﬁrmed the limited activity of PN on normal cells.
PN inhibited the development of resistance induced by Mitox and
DOX
As reported in Materials and Methods, MDA-MB231 cells were
submitted to treatment with Mitox or DOX for a total selection
time of 25 days, in order to produce resistant cells. At the end,
selected cells were employed to evaluate the effects of various
doses of Mitox, DOX and PN on their viability. To ascertain the
acquisition of resistance, IC50 values were at ﬁrst calculated from
dose–response curves, then the resistance indices (RIs) were
obtained by evaluating the ratio between the corresponding IC50
and the IC50 measured for parental cells, for each case of drug
treatment. Figures 2a and b show dose–response curve, IC50 and
RI values for the three compounds and for each cell condition. The
results demonstrate that the treatment produced resistant cells, as
represented by an increase of RIs to 4.5, 3.1 and 2.7 values with
Mitox-treated cells and to 3.0, 3.5 and 3.1 values with DOX-treated
cells, depending if the resistance was evaluated toward PN, Mitox
or DOX, respectively.
It is known that PN at high doses (10–20 μM) exerted cytotoxic
effects on MDA-MB231 cells by stimulating ROS generation,30 but
was unable to induce resistance in these cells. However, when PN
was added to Mitox or DOX, over the total selection time it
prevented the development of resistance. In particular, PN caused
a partial, but considerable effect, when it was added to Mitox, as
shown by IR values (Figure 2a), whereas it completely prevented
resistance when added to DOX (Figure 2b).
This preventive effect of PN was clearly observed at a
concentration equal or superior to 2.0 μM. This dose was chosen
for our experiments, because it did not induce toxic effects on
cultured cells, when administered alone.
Moreover, PN was added to the samples 2 days before the
drugs, as this resulted in a higher effect on the prevention of
resistance than when PN was added together with the drugs.
These results suggest that PN induced molecular changes in the
cells, which opposed the development of resistance.
The inhibitory effect of PN on development of resistance was
contrasted by the addition of 2.0 mM NAC to the samples utilized
to study dose–response curves. In particular, the PN effect was
abolished by NAC when the resistance was ascertained towards
the same PN and markedly reduced when resistance was
ascertained towards Mitox and DOX (Figures 2a and b). The effect
exerted by NAC suggested that PN prevented the development of
resistance inducing changes, which favour ROS generation.
Nrf2 and correlated proteins were upregulated in resistant cells, an
effect which was partially prevented by PN
Through western blotting analysis on whole-cell lysates, it was
shown that the development of resistance in MDA-MB231 cells
was accompanied by overexpression of some factors correlated
with antioxidant response or cell survival. At ﬁrst, we evaluated
the expression of Nrf2,27 a critical regulator of antioxidant
activities. Then our study was extended to MnSOD and catalase,
two activities which control the intracellular level of ROS;32,33
HSP70,34 a heat shock protein which inhibits apoptosis and
induces drug resistance; P-gp,35 a transporter that controls the
efﬂux of anticancer drugs and ﬁnally Bcl-2,36 a fundamental
antiapoptotic protein.
Nrf2 level was found to be enhanced by 110 and 85% in cells
selected with Mitox and with DOX, respectively, in comparison
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with parental cells (Figures 3a and b). Moreover, western blotting
analysis demonstrated that the nuclear content of Nrf2 with
respect to the total content of the protein increased from 40% in
parental cells to 75% in both the selected cells (not shown). In
addition, the level of the other ﬁve proteins examined, namely
MnSOD, catalase, HSP70, Bcl-2 and P-gp, were markedly increased
in selected cells (Figure 3a). In particular, the increments for Mitox-
selected cells ranged from 50% for catalase to 270% for MnSOD,
whereas for DOX-selected cells the variation was from 60% for
catalase to 180% for MnSOD (Figure 3b).
Previously31 we showed that PN downregulated Nrf2 expression
in stem-like cells derived from MDA-MB 231 cells. This ﬁnding
suggested to us that PN may contrast the increased expression of
Nrf2 in selected cells. In accordance, our results showed that when
2.0 μM PN was added in association with the drugs over the total
selection time, the increments of both Nrf2 and correlated factors
were signiﬁcantly reduced both in Mitox- and DOX-selected cells.
In particular, co-treatment reduced by about 50% the increment of
Nrf2 expression in both selected cells (Figures 3a and b). For the
other proteins the reduction was always higher than 40% and in
some cases (Bcl-2 and P-gp) the increments were completely
suppressed. Finally, the relative level of nuclear Nrf2 was also
decreased in cells submitted to combined treatment to 40–45% of
the total content (not shown).
Cell ability to generate ROS was inhibited in resistant cells. Also,
this effect was partially prevented by PN
We evaluated in some experiments the ability of selected cells, in
comparison with parental cells, to produce ROS in response to a
suitable stimulation. As PN, as previously shown,30 is a valid
inductor of ROS in MDA-MB231 cells, in these experiments the
cells were stimulated for 1 h with 10 μM PN and then submitted to
DCF test,37 using cytoﬂuorimetric analysis. Parental cells are
particularly able to generate ROS, as DCF-positive cells increased
from 33.8% in non-stimulated cells (basal level) to 53.9% after
stimulation (Figure 4). Interestingly, the basal level of DCF-positive
cells fell from 33.8% in parental cells to 15.4% in Mitox-selected
cells and to 27.2% in DOX-selected cells. Similar decrements were
observed also when the cells were treated over the selection time
with the drugs plus PN. These results suggested that low levels of
intracellular ROS were present in the surviving cells at the end of
the selection time. It is interesting to note that the amount of DCF-
positive cells was not signiﬁcantly modiﬁed by stimulation neither
Figure 1. The effects exerted by Mitox and DOX on the growth of cultured HMEC and MDA-MB231 cells. The inﬂuence of PN. Cells (2 × 105)
were seeded in 25 cm2 ﬂasks in 7.5 ml of medium. Viability was measured every 2 days by means of Trypan Blue assay. (a) HMEC and MDA-MB
231 cells cultured in medium in the absence or the presence of 2.0 μM PN. Growth of untreated MDA-MB 231 cells was stopped at 10th day
when the cultures were near to the conﬂuence, whereas in the presence of PN was stopped at 16th day. (b) Cells cultured in medium
containing 10 nM Mitox without or with 2.0 μM PN. (c) Cells cultured in medium containing 20 nM DOX without or with 2.0 μM PN. All the
values are the means± S.D. of four different experiments.
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in Mitox- nor in DOX-selected cells. Therefore, we concluded
that selected cells were unable to produce ROS, even
when submitted to a suitable stimulation. Instead, cells treated
during the selection time with drugs plus PN were capable of
generating ROS, as indicated by the signiﬁcant responses
following adequate stimulation. In particular DCF-positive cells
increased from 14.5% to 20.9% (P o0.01) in cells treated with
Mitox plus PN and from 26.0% to 32.2% (P o0.01) in cells treated
with DOX plus PN.
Knockdown of Nrf2 decreased the expression of target activities
and prevented development of drug resistance
It is known that Nrf2 controls transcriptional activity of many
antioxidant and detoxifying genes. Moreover, high levels of Nrf2
were found in tumour cells resistant to chemotherapeutic drugs.25
This ﬁnding was conﬁrmed by the present paper, showing that
acquisition of resistance was accompanied by enhancement of
Nrf2 expression. In addition, brusatol,38 a compound that
decreases Nrf2 level, sensitized tumour cells to the drugs.
Therefore, we hypothesized that PN can exert its effect against
acquisition of drug resistance by preventing the increment of Nrf2
expression, which occurs during the selection time, and conse-
quently also those of the correlated antioxidant and protective
factors. In order to demonstrate in MDA-MB231 cells the relation-
ships between Nrf2 and antioxidant activities, as well as between
Nrf2 and the acquisition of resistance, we silenced Nrf2 expression
in parental MDA-MB231 cells by using Nrf2 small interfering RNA
(siRNA). Western blotting analysis showed (Figure 5) that, after
24 h from transfection, the level of total Nrf2 was strongly
diminished in cells transfected with Nrf2 siRNA in comparison with
cells treated with control siRNA. In addition, the relative level of
nuclear Nrf2 decreased by 50% compared with control (not
shown). Signiﬁcant decrements (30–40%) were also observed for
the intracellular levels of NQO1, HSP70, MnSOD catalase and Bcl-2
(Figure 5). These results demonstrated that these activities are
under Nrf2 control in MDA-MB231 cells.
PN prevents drug resistance in MDA-MB231 cells
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In other experiments, parental MDA-MB231 cells were at ﬁrst
transfected with Nrf2 siRNA and then treated for 7 days with
10 nM Mitox. As shown in Table 1, in these cells IC50 values and
consequently the RIs, measured towards the three selected
compounds (PN, Mitox and DOX), were much lower than the
values ascertained for cells submitted to the identical treatment
with Mitox, but after transfection with control siRNA. These results
demonstrated that down-regulation of Nrf2 and correlated
proteins partially prevented acquisition of resistance in cells
treated with Mitox.
As Nrf2 stimulates the expression of antioxidant activities, we
hypothesized that the enhancement of Nrf2 can be responsible for
inhibition of ROS generation, whereas on the contrary down-
regulation of Nrf2 can favour production of ROS. To demonstrate
Figure 2. MDA-MB231 cells developed resistance under the exposure to Mitox or DOX. PN partially prevented this event. MDA-MB231 cells
(5 × 105) were seeded in 75 cm2 ﬂasks in 15.0 ml of medium. Selection with Mitox and DOX was performed as reported in methods. In order to
investigate whether PN prevents the development of resistance, cells were pre-treated for 2 days with 2.0 μM PN alone, then the drugs were
added and the combined treatment was protracted for the total selection time. At the end cells of all the conditions were maintained for
other 5 days in medium without both drugs and PN. Panels a and b report results concerning cells submitted to selection with Mitox or DOX,
respectively. In order to ascertain the degree of resistance reached in the various conditions, the cells were collected and employed, as
reported in methods, to test the effect on viability exerted for 48 h by various doses of (I) PN, (II) Mitox and (III) DOX. Viability was ascertained
for the following conditions: parental cells (--○--); cells treated with drugs to acquire resistance (--●--); cells treated with drugs plus 2.0 μM PN
(--□--); cells treated with drugs plus PN as in the previous condition, but with the difference that 2.0 mM NAC were added in the samples
performed to test viability (--■---). Viability was assessed by MTT assay and reported for each condition as percentage of cells treated with
vehicle only. For each compound tested and for each condition the Figures report dose–response curve, IC50 value calculated from dose–
response curves and the RI. The results are the means of four different experiments± S.D. *Po0.01 versus parental cells; #Po0.01 versus cells
treated with Mitox or DOX plus PN.
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the validity of this hypothesis, Nrf2-silenced cells were submitted
to DCF test. Cytoﬂuorimetric analysis, reported in Figure 6a,
showed that in non-stimulated conditions the proportion of DCF-
positive cells was higher in Nrf2-silenced cells than in cells
transfected with control siRNA (control cells). Moreover, this
proportion increased after stimulation of Nrf2-silenced cells for 1 h
with low doses of PN (1-2 μM), whereas a much minor effect was
observed in control cells. However, at higher doses of PN the
difference between the two conditions was no more evident. To
conﬁrm these results we followed another procedure, based on
ﬂuorescence microscopy. As shown in Figure 6b, in Nrf2-silenced
cells ﬂuorescent cells appeared already in non-stimulated
conditions and its number increased after stimulation for 1 h with
1–2 μM PN, whereas in the control ﬂuorescent cells were not
visible before stimulation and appeared in a modest number after
stimulation with low doses of PN.
These results, taken together, showed that silencing of Nrf2 in
MDA-MB231 cells enhanced cells ability to generate ROS, in
accordance with the decrement of the expression of the antioxidant
and cytoprotective activities observed in the same silenced cells.
These results are in agreement with the effect induced by PN, when
it was added to the drugs during the selection time. In fact, PN in
this case contrasted the overexpression of Nrf2 and at the same
time preserved cell ability to generate ROS.
Figure 3. Development of resistance induced overexpression of Nrf2 and correlated proteins, an effect which was partially prevented by PN.
MDA-MB231 cells were submitted to treatment with Mitox or DOX, as reported in methods, in order to develop the resistance. In some
samples 2.0 μM PN were added two days before the drugs and maintained for the total selection time together with the drugs. Western
blotting analysis was performed as reported in methods. (1) Parental cells; (2) cells selected with Mitox or DOX; (3) cells treated with Mitox or
DOX plus PN. (a) Images of western blotting analysis. Results are representative of four different experiments. (b) Estimation by densitometric
analysis of the intensity of the bands. The results are the means of four distinct experiments± S.D. *Po0.01 versus parental cells; #Po0.01
versus cells treated with Mitox or DOX plus PN.
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Figure 4. The development of resistance inhibited ROS generation. Addition of 2.0 μM PN to the drugs during the selection time reduced the
inhibitory effect on ROS generation. Parental and resistant cells were treated for 1 h with 10 μM PN in order to stimulate production of ROS. At
the end 10 μM H2-DCFDA were added for 20 min, then the cells were collected and employed for cytoﬂuorimetric analysis. Results are
representative of three different experiments.
PN prevents drug resistance in MDA-MB231 cells
D Carlisi et al
7
Ofﬁcial journal of the Cell Death Differentiation Association Cell Death Discovery (2017) 17078
DISCUSSION
It is known that low levels of intracellular ROS assure survival and
viability of both resistant39 and stem cells.40,41 In both cases, the
low level of ROS seems to be correlated with upregulation of
antioxidant activities. Instead high levels of ROS are harmful to the
cells favouring DNA damage and cell death by apoptosis or
necrosis.42 It is reasonable to suppose that in order to maintain
ROS generation at low levels, cells increased Nrf2 expression. The
activity of Nrf2 is under the control of Keap1,43–45 a factor which
interacts in the cytoplasm with Nrf2, inducing its ubiquitination
and proteasomic degradation. Various stress conditions lead to
the modiﬁcation of a cysteine residue in Keap1, causing Nrf2
release and its consequent translocation into the nucleus, where it
induces transcriptional activity of genes bearing the antioxidant
response element (ARE). Thus, stress conditions, through Keap1,
control cellular redox homeostasis. Accumulating evidence
suggests that by stimulating a wide range of genes, Nrf2 exerts
a crucial role in the protection against oxidative stress, in
detoxiﬁcation of drugs and cytoprotective events.45 Among the
enzymes involved in the protection against oxidative stress,
MnSOD and catalase32 control the intracellular level of ROS, with
MnSOD converting superoxide anion to hydrogen peroxide, which
is further converted into water by catalase. It is known that both
the activities are under the control of Nrf2 (Kobayashi and
Yamamoto44) and that their expression markedly increases after
Nrf2 stabilization by D3T.46 In addition, Nrf2 intervenes in the
upregulation of P-gp,47 a member of ABC transporter family, that
favours the efﬂux of anthracyclines and taxane.35 Moreover, a
closed relationship exists between Nrf2 and HSP70, as sulfhydryl-
reactive inducers of the Keap1/Nrf2/ARE pathway upregulate
HSP70.48 HSP70 is a well-known family of the chaperone proteins
HSPs,49–51 which are enhanced by cellular stress, such as
inﬂammation, high temperature and oxidative stress, and are
involved in the folding of synthetized polypeptide and in the
interaction with apoptotic factors and consequently in their
inhibition. Owing to this last ability, HSP70 family supports the
survival of cells and thus favours drug resistance. Finally, Nrf2
exerts a cytoprotective effect also by inducing the transcription of
Bcl-2 and Bcl-XL, two fundamental inhibitors of apoptosis.52,53
There is evidence that cell resistance is correlated with Nrf2
expression.54 In particular, it is known that Nrf2 induced
radioresistance.55 Moreover, Nrf2 overexpression enhanced resis-
tance of cultured cells to cisplatin, DOX and etoposide.25
Accordingly, also resistance to tamoxifen in breast cancer patients
was correlated with increased expression of both Nrf2 and other
antioxidant proteins.56 Inversely, downregulation of Nrf2, caused
by transfection of Nrf2 siRNA26 or by the inhibitor brusatol,38
enhanced drug susceptibility of tumour cells. Similarly, epigallo-
catechin-3-gallate,57 an effective inhibitor of Nrf2, efﬁcaciously
prevented resistance against tamoxifen. In conclusion, drug
resistance, high expression of Nrf2, and correlated proteins and
low ability to generate ROS are three aspects closely linked
each other.
To improve the effectiveness of chemotherapeutic treatment of
TNBC forms we chose to associate PN to the drugs, in order to
increase their activity by preventing development of drug
resistance. This choice was suggested by the observation58 that
PN enhanced DOX cytotoxicity in human lung cancer cells.
Moreover, our previous study on the cytotoxic effects induced by
PN on stem-like cells, derived from MDA-MB231 cells,31 suggested
that PN can prevent drug resistance by decreasing Nrf2. To
ascertain the role of PN we submitted MDA-MB231 cells to
selection treatment with Mitox or DOX either in the absence or in
the presence of 2.0 μM PN. In the absence of PN, exposure to the
drugs increased IC50, reaching values about threefold higher than
in parental cells and in addition caused overexpression of Nrf2
protein. This effect was associated with the increase of some
proteins, such as MnSOD, catalase, HSP70, Bcl-2 and P-gp, which
are upregulated by Keap 1/Nrf2/ARE pathway and exert important
roles as antioxidant and cytoprotective activities. Finally, in these
cells the ability to generate ROS was particularly diminished, in
accordance with the high expression of antioxidant activities.
When PN was added to Mitox or DOX, over the total selection
time required to induce resistance, it partially prevented Nrf2
overexpression, as well as diminished the levels of the correlated
proteins. Owing to the effect on MnSOD and catalase, the
antioxidant power decreased and the cells maintained the ability
to generate ROS under an adequate stimulus. The concomitant
decrease in the levels of the cytoprotective agent HSP70
(Bozaykut et al.49) and the anti-apoptotic factor Bcl-2 (Zhou
et al.55) contributed to reduce the defence mechanisms of the
cells. Consequently, RI values decreased and the cells continued to
Figure 5. Silencing of Nrf2 decreased the expression of antioxidant
and cytoprotective proteins. Nrf2 was silenced in parental MDA-
MB231 cells, as reported in methods. After 24 h whole cellular
extracts were prepared and submitted to western blotting analysis.
(a) Images of western blotting analysis. Results are representative of
four different experiments. (b) Estimation by densitometric analysis
of the intensity of the bands. The results are the means of four
distinct experiments± S.D.
PN prevents drug resistance in MDA-MB231 cells
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Table 1. Knockdown of Nrf2 prevented in MDA-MB231 cells the development of resistance induced by Mitox
Dose–response curve towards: IC50 values (μM) RI values
Control siRNA Nrf2 siRNA Control siRNA (b/a) Nrf2 siRNA (b/a)
a b a b
PN 5.2± 0.50 16.2± 1.5 5.0± 0.40 9.0± 0.95 3.1± 0.33 1.8± 0.20
Mitox 0.7± 0.08 1.4± 0.15 0.9± 0.08 1.0± 0.10 2.0± 0.20 1.1± 0.12
DOX 0.8± 0.08 1.6± 0.16 0.9± 0.08 1.2± 0.12 2.0± 0.22 1.3± 0.15
Abbreviations: a, parental cells; b, mitox-resistant cells; DOX, doxorubicin; Mitox, mitoxantrone; Nrf2, NF-E2-related factor 2; PN, parthenolide; RI, resistance
index; siRNA, small interference RNA. Parental MDA-MB231 cells were transfected with Nrf2 siRNA or with control siRNA, as reported in Materials and Methods.
After 24 h, the cells were submitted for 7 days to treatment with 10 nM Mitox in order to induce resistance. At the end, the cells were collected, counted and
employed to test, in comparison with untreated cells, the effect exerted on cell viability by various doses of PN, Mitox and DOX. Dose–response curves (not
shown) permitted to calculate IC50 and RI values reported in the Table. Results are the means± S.D. of three different experiments.
Figure 6. Silencing of Nrf2 in parental MDA-MB231 cells enhanced the intracellular level of ROS and the effect of PN on ROS generation. Nrf2
was silenced in parental MDA-MB231 cells as reported in methods. After 5 h of transfection the cells were employed, as described in methods,
for (a) cytoﬂuorimetric analysis and (b) visualization by ﬂuorescence microscope. Results are representative of three different experiments.
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die, whereas an amount of cells remained viable in the samples
treated with the drugs alone without PN.
Our results strongly suggested that Nrf2 has a crucial role in the
control of antioxidant power and in the fate of MDA-MB231 cells.
In fact silencing of Nrf2 decreased resistance of cells and the levels
of antioxidant proteins, whereas the ability to generate ROS
increased. In conclusion, knockdown of Nrf2 caused similar effects
to those ascertained when PN was added to the drugs during the
selection treatment.
It is interesting to note that PN was unable to induce resistance,
because chemoresistance is correlated with the increment of
antioxidant activities and the reduction of the intracellular ROS
level, whereas PN induces opposite effects. Instead, cells which
acquired resistance through the exposure to drugs exhibited
resistance also towards PN, because high levels of Nrf2 and
antioxidant proteins prevented PN cytotoxicity, which is based on
stimulation of ROS generation.
An important question is whether the increase in Nrf2
expression, which is typical of resistant cells, is stable or can be
lost after a prolonged treatment with the same PN or other
compounds capable of down-regulating Nrf2 expression. We shall
elaborate further on this interesting aspect in a future work.
It has been shown that the promoter region of Keap1 gene is
hypermethylated in many lines of cancer cells, such as colorectal
cancer59 and lung cancer.60 This hypermethylation is responsible
for inactivation of Keap1 function with the concomitant activation
of Nrf2, which is associated with cancer development and drug
resistance.61 Genistein, a natural isoﬂavone, inhibits the activity
and the expression of DNMT1.62 Owing to this property genistein
decreases DNA methylation in the promoter region of tumour
suppressor genes,62 as well as in that of keap1 gene. As a
consequence genistein increases the expression of Keap1
mRNA.63 This effect reduces Nrf2 transition to the nucleus with
the consequent decrement of the antioxidant activities and
increment of ROS level. By inhibiting DNMT1 activity, through
the alkylation of cysteine 1226 in the catalytic domain of the
enzyme, PN also causes global DNA hypomethylation.28,64 There-
fore, we suggest that PN, like genistein, can decrease methylation
in the promoter region of the Keap1 gene and consequently can
reduce Nrf2 level in the nucleus preventing the acquisition of drug
resistance. It seems possible that the action of PN on Nrf2 can
really consist in limiting, by means of a similar mechanism, the
overexpression of this protein which occurs in particular cases,
such as in resistant cells.
Chemoresistance leads to the survival of a heterogeneous
population of tumour cells. A small fraction of these cells, named
cancer stem cells (CSCs),1,15,65 can give rise to a new recurrent
form of the tumour, because they are capable of self-renewal and
differentiation. It is known that CSCs are resistant to therapy,
because they exhibit one or more defence mechanisms. Therefore,
after drug treatment the proportion of these cells increases. This
favours the action of stimulatory agents, inducing the proliferation
of CSCs and the production of a recurrent form of the tumour,
thus mirroring the complexity and the cellular heterogeneity of
the primary form. Previously31 we produced mammospheres from
three lines of TNBC cells, including MDA-MB231 cells, and
demonstrated that PN, through its cytotoxic effects on stem-like
cells, prevented their production.
Our study demonstrates that PN prevented the acquisition of
resistance induced by Mitox and DOX treatment in MDA-MB231
cells. This effect was mediated by inhibition of overexpression of
both Nrf2 and its target activities. Therefore, within MDA-MB231
cell lines, PN not only exerts toxic effects on stem-like cells, which
are responsible for tumour recurrence, but also prevents drug
resistance. However, because PN exhibits a scarce bioavailability,
we suggest that DMAPT, an analogue of PN, which shows the
same mechanism of action of PN, but has enhanced
bioavailability, can be considered in association with the drugs
for a new therapeutic strategy for TNBCs.
MATERIALS AND METHODS
Chemicals and reagents
PN, Mitox, DOX and all chemicals, except when stated otherwise, were
supplied by Sigma-Aldrich (Milan, Italy). Stock solution of PN was prepared
in dimethylsulfoxide (DMSO) and then diluted to ﬁnal concentration in the
culture medium. DMSO employed as vehicle never exceeded 0.04% and
had no discernible effects on cells in comparison with the control. Mitox
and DOX were prepared in ddH2O and diluted to ﬁnal concentration in the
culture medium.
Cell cultures
The human breast cancer cell line MDA-MB231 was purchased from
Interlab Cell Line Collection (Genova, Italy) and grown as monolayer in
DMEM culture medium, supplemented with 10% fetal calf serum, 2.0 mM
glutamine, 1% non-essential amino acids. HMEC were purchased from
Lonza (Walkersville, MD, USA) and grown according to the manufacturer’s
instructions. Cells were grown in an incubator at 37 °C in a humidiﬁed
atmosphere containing 5% CO2.
Cell viability
Cell viability was ascertained by MTT colorimetric assay, as previously
described.30,31
For the experiments reported in Figure 1, HMEC and MDA-MB231 cells
(2 × 105) were seeded in 25 cm2 ﬂask in 7.5 ml of DMEM culture medium
containing the drugs. Samples were evaluated every day by light
microscopic observation. At established times, cultures were detached
and an aliquot of cell suspension was diluted with 0.4% trypan blue and
counted in a hemocytometer under a microscope at × 200 magniﬁcation.66
The dye is admitted by dead cells, which appear blue, whereas it is
excluded by viable cells, which appear transparent. In our experiments the
number of the transparent, viable cells was counted. The counting was
repeated three fold for each condition and the mean of the three values
was considered for the results.
Generation of resistant cells
In order to produce drug resistant cells MDA-MB231 cells (5 × 105) were
seeded in 75 cm2 ﬂask in 15 ml of medium. Two procedures were followed.
Procedure I: cells were treated for 15 days with 5 nM Mitox and then for
other 10 days with 10 nM Mitox. Procedure II: cells were treated for 15 days
with 10 nM DOX and then for other 10 days with 20 nM DOX.
PN was employed in order to prevent the development of drug
resistance. In this case, MDA-MB231 cells were pre-treated for 2 days with
2.0 μM PN in 75 cm2 ﬂask. Then the cells were collected, counted, seeded
(5 × 105 cells) in 75 cm2 ﬂask in 15 ml of medium and treated following one
of the above reported procedures. During this treatment, PN (2.0 μM) was
always maintained in the medium together with Mitox or DOX. After
25 days the cells of all the conditions remained for other 5 days in the
medium without both drugs and PN. Finally the cells were collected and
counted. In order to ascertain resistance towards Mitox, DOX and PN, cells
(8 × 103/well) were plated in 200 μl of DMEM in a 96-well plate and treated
for 48 h with various doses of the three compounds. Control samples were
treated with vehicle only. Cell viability was evaluated by MTT assay. Dose–
response curve permitted to calculate for every condition IC50, which
corresponds to the dose capable of inhibiting cell proliferation by 50%. The
degree of resistance was calculated by the RI, which corresponds for every
condition to the ratio between the related IC50 and the IC50 calculated for
the parental cells.
Evaluation of ROS generation
Intracellular ROS were detected using the redox-sensitive ﬂuorochrome H2-
DCFDA (Molecular Probe, Life Technologies, Eugene, OR, USA). Cells (105/
well) were seeded in six-well plates and, after 24 h, were incubated with PN
for 1 h. At the end the cells were washed with PBS and incubated with
10 μM H2-DCFDA in Hank’s balanced salt solution (HBSS) for 20 min at 37 °
C in darkness. Then the cells were collected, centrifuged at 120× g for
5 min, resuspended in PBS and analysed using an Epics XL ﬂow cytometer
with excitation and emission settings at 480 and 525 nm, respectively.
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Intracellular ROS were also directly visualized by means of a ﬂuorescence
microscope.31 In this case, cells were seeded in 96-well plates (8 × 103/well)
and after 24 h were stimulated with PN for 1 h, washed with PBS and
incubated in 100 μl of 10 μM H2-DCFDA in HBSS for 20 min at 37 °C in
darkness. Finally, H2-DCFDA was replaced with PBS and after other 20 min
ﬂuorescence produced by oxidation of ﬂuorochrome was visualized with a
Leica microscope equipped with a DC300 F camera at × 200 magniﬁcation
using FITC ﬁlter (excitation wavelength of 485 nm and emission
wavelength of 530 nm).
Transient gene silencing by siRNA
siRNAs against Nrf2 (Nrf2 siRNA) and scrambled siRNA (control siRNA), as a
negative non-silencing control, were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA).
Cells (105/well) were seeded in six-well plates and cultured in antibiotic
and serum-free DMEM supplemented with 2.0 mM glutamine and 1% non-
essential amino acids, until ~ 50% conﬂuence. Then, cells were transfected
with 50 nM siNrf2 in the presence of 5 μl Lipofectamine 2000 (Invitrogen
Life Technologies, Monza, Italy) in a ﬁnal volume of 1 ml serum-free
medium.67 The reaction was stopped after 5 h replacing the culture
medium with fresh DMEM + 10% FBS. After 24 h from transfection,
silenced cells were employed for the experiments.
Western blotting analysis
Cell lysates and protein samples were prepared as previously reported.67
Equal amounts of protein samples (20 μg per lane) were run in a SDS-
polyacrylamide gel electrophoresis and then transferred to a nitrocellulose
membrane. All analyses were performed using speciﬁc primary antibodies
against: Bcl-2, Nrf2, MnSOD and P-gp, which were supplied from Santa
Cruz Biotechnology; HSP70 and NQO1 from Cell Signaling Technology
(Beverly, MA, USA); and catalase and β-actin from Sigma-Aldrich. Then, the
detection was developed by using a secondary antibody conjugated with
horseradish peroxidase (Santa Cruz Biotechnology). The protein bands
were revealed with an enhanced chemiluminescence detection system
(Bio-Rad, Hercules, CA, USA) and visualized by ChemiDoc XRS system (Bio-
Rad) and Quality One 4.5.2 software (Bio-Rad). The intensity of the protein
bands was quantiﬁed by densitometric analysis using SMX Image software
(Bio-Rad). The correct protein loading was ascertained by red Ponceau
staining and immunoblotting for β-actin. All the blots shown are
representative of at least four different experiments.
Statistical analysis
Results are presented as means± S.D. of data obtained from at least three
independent experiments. Data were analysed using Student’s t-test. A P-
value below 0.01 was considered signiﬁcant.
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